For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Protagonist Therapeutics, Inc.

USPTO Granted Patents = 35

EPO Patents = 9

Forward Citations = 420

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Ashok Bhandari (29 out of 31 patents)

Brian Troy Frederick (27 out of 29 patents)

Gregory Thomas Bourne (19 out of 21 patents)

4. Dinesh Vinoobhai Patel (17 out of 60 patents)

5. David Y Liu (15 out of 108 patents)

6. Larry C Mattheakis (11 out of 20 patents)

7. Jie Zhang (11 out of 12 patents)

8. Xiaoli Cheng (9 out of 10 patents)

9. Mark Leslie Smythe (9 out of 14 patents)

10. Genet Zemede (8 out of 14 patents)

11. Simone Vink (6 out of 6 patents)

12. Praveen Madala (6 out of 6 patents)

13. Anne Pernille Tofteng Shelton (6 out of 6 patents)

14. Jacob Ulrik Fog (6 out of 14 patents)

15. Chengzao Sun (3 out of 3 patents)

Core Competencies:

Peptide Inhibitors

Interleukin-23

Inflammatory Diseases

Hepcidin Analogues

Opioid Agonist Peptides

Integrin Antagonists

Cyclic Peptides

Thioether Peptides

Dimer Antagonists

Monomer Antagonists

Inflammatory Bowel Diseases

Peptide Mimetics

35 patents: Sort by Forward Citations

1. 12673974 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2026-07-07),

2. 12655185 - PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES (2026-06-16),

3. 12552836 - PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES (2026-02-17),

4. 12478617 - Lipidated peptide inhibitors of interleukin-23 receptor (2025-11-25),

5. 12269856 - Hepcidin analogues and uses thereof (2025-04-08),

6. 12234300 - Conjugated hepcidin mimetics (2025-02-25),

7. 12018057 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2024-06-25),

8. 11939361 - Compositions of peptide inhibitors of Interleukin-23 receptor (2024-03-26),

9. 11884748 - Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases (2024-01-30),

10. 11845808 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases (2023-12-19),

11. 11840581 - α4β7 thioether peptide dimer antagonists (2023-12-12),

12. 11807674 - Hepcidin analogues and uses thereof (2023-11-07),

13. 11753443 - Conjugated hepcidin mimetics (2023-09-12),

14. 11472842 - Analogues of hepcidin mimetics with improved in vivo half lives (2022-10-18),

15. 11111272 - α4α7 peptide monomer and dimer antagonists (2021-09-07),

Company Overview

Protagonist Therapeutics, Inc. is a biopharmaceutical company based in Newark, California, focused on developing novel therapies for gastrointestinal and other serious diseases. The company specializes in peptide-based therapeutics, leveraging its proprietary technology platform to design and optimize oral and injectable drug candidates. Protagonist is committed to advancing innovative treatments that address unmet medical needs, with a strong emphasis on research and development in the field of drug discovery and development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

35 Patents

#15 in Newark, CA

#2,306 in California

#9,740 in US

#19,148 in the World

Newark, CA, United States of America

Protagonist Therapeutics, Inc.

Forward Citations = 420

45 inventors:

Ashok Bhandari (29 out of 31 patents)

Brian Troy Frederick (27 out of 29 patents)

Gregory Thomas Bourne (19 out of 21 patents)

4. Dinesh Vinoobhai Patel (17 out of 60 patents)

5. David Y Liu (15 out of 108 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Protagonist Therapeutics, Inc.. Retrieved from https://idiyas.com/company/protagonist-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…